Evidence from this systematic review shows that breviscapine injection in combination with antihypertensive drugs can improve clinical efficacy and creatinine clearance rate and reduce serum creatinine, blood urea nitrogen, 24-hour urinary protein, and beta-2-microglobulin in hypertensive nephropathy patients. This evidence concerns the gene B2M and hypertensive nephropathy.